Pfizer to Partner with Imcyse for Potential Rheumatoid Arthritis Treatment
The companies have entered into a research collaboration and license agreement for the potential treatment of rheumatoid arthritis via Imcyse’s RA program based on its Imotope technology.
Pfizer and Imcyse, a Belgium-based clinical-stage biopharmaceutical company, announced on Feb. 3, 2021 that they have entered into a research collaboration and license agreement for the potential treatment of rheumatoid arthritis (RA) via Imcyse’s RA program based on its Imotope technology.
Under the terms of the agreement, Imcyse will receive an undisclosed upfront payment and will receive up to $180 million in milestone payments, Imcyse said in a company press release. Pfizer will be responsible for the clinical development and commercialization activities for the program.
“This license agreement constitutes a great endorsement and a sign of confidence in our Imotope technology platform from one of the leading pharmaceutical companies in the world. We are excited to expand our successful collaboration to develop Imotopes for RA, a prevalent autoimmune disorder,” said Denis Bedoret, Imcyse CEO, in the press release. “It is our ultimate goal to develop curative treatments for autoimmune disorders for the benefit of patients worldwide. For diseases such as RA, this can be best accomplished with the help of partners such as Pfizer.”
“Pfizer is committed to addressing the needs of patients in [r]heumatology, and the Imcyse technology platform offers a unique scientific approach that we look forward to exploring further,” added Mike Vincent, chief scientific officer, Pfizer Inflammation and Immunology, in the press release.
Source: Imcyse
